{"id":"NCT00992589","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)","officialTitle":"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed Release Rabeprazole in 1- to 11-Month-Old Pediatric Subjects With Symptomatic/Gastroesophageal Erosive Reflux Disease (GERD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2009-10-09","resultsPosted":"2013-05-22","lastUpdate":"2013-05-22"},"enrollment":344,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux"],"interventions":[{"type":"DRUG","name":"Rabeprazole sodium 5 mg","otherNames":[]},{"type":"DRUG","name":"Rabeprazole sodium 10 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rabeprazole sodium 5 mg","type":"EXPERIMENTAL"},{"label":"Rabeprazole sodium 10 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of gastrointestinal esophageal reflux disease (GERD) in infants 1 to 11 months of age.","primaryOutcome":{"measure":"Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward)","timeFrame":"Baseline, Week 8","effectByArm":[{"arm":"Double-Blind Placebo","deltaMin":-0.8,"sd":1.58},{"arm":"Double-Blind Rabeprazole Sodium 5 mg","deltaMin":-0.8,"sd":1.55},{"arm":"Double-Blind Rabeprazole Sodium 10 mg","deltaMin":-1.6,"sd":3.63},{"arm":"Double-Blind Rabeprazole Sodium Total","deltaMin":-1.2,"sd":2.79}],"pValues":[{"comp":"OG000 vs OG003","p":"0.168"}]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":81,"countries":["United States","Australia","Belgium","Bulgaria","Denmark","Hungary","Israel","Netherlands","Poland","South Africa"]},"refs":{"pmids":["26628445","24121146","23689261"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":344},"commonTop":["Pyrexia","Diarrhoea","Upper Respiratory Tract Infection","Nasopharyngitis","Constipation"]}}